Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rituximab + Chemo for Grade 3 Follicular Lymphoma

Clin Lymphoma Myeloma Leuk; ePub 2017 Jun 16; Yuan, et al

Publish date:: June 21, 2017

Rituximab with anthracycline-based chemotherapy significantly improved survival in patients with grade 3 follicular lymphoma (FL) in a retrospective analysis involving 749 individuals.

Participants included people with FL1/2 (n=87); FL3, including 3 subtypes (n=84); and diffuse large B-cell lymphoma (DLBCL; n=411). All were treated with rituximab and anthracycline-based chemotherapy. There was also a historical cohort of FL3 patients who received only anthracycline-based chemotherapy (n=167). Among the results:

The FL3 group had a significantly better overall and event-free survival than their counterparts who received only chemotherapy.
They also survived longer than DLBCL patients.
FL3 subtypes experienced similar overall survival.
FL3B had a shorter event-free survival than other FL3 subtypes.
FL3B and DLBCL outcomes were similar.
The other 2 FL3 subtypes experienced better outcomes than DLBCL patients.
<Half of FL3B patients have relapsed.
<20% of the other FL3 subtypes have relapsed.

Citation:

Yuan, J, Greiner T, Fu K, et al. Rituximab improves the outcome of patients with grade 3 follicular lymphoma receiving anthracycline-based therapy. [Published online ahead of print June 16, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.06.006.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in Lymphoma & Plasma Cell Disorders

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Outcomes Post-AlloSCT in DHL/DEL Lymphomas, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Anthracycline-Related CV Dysfunction Evaluated, Cancer; ePub 2017 Nov 7; Armenian, Mertens, et al

Adcetris Approved for Primary Cutaneous ALCL, FDA news release; 2017 Nov 9